Interpreting patient-reported outcomes from clinical trials in COPD: A discussion

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 3069-3078

  Jones, Paul W ^a,b   Rennard, Stephen ^c,d   Tabberer, Maggie ^b   Riley, John H ^b   Vahdati Bolouri, Mitra ^b   Barnes, Neil C ^b,e  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NEBRASKA MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

COPD; Data interpretation; Patient centered outcomes research; St George s Respiratory Questionnaire; Statistical

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LONG ACTING BETA 2 AGONIST; LONG ACTING MUSCARINIC ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ANALYSIS; ASSESSMENT OF HUMANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DISEASE SEVERITY; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GRADE; HUMAN; METHODOLOGY; MINIMUM CLINICALLY IMPORTANT DIFFERENCE; PARAMETERS; PATIENT REPORTED OUTCOME; PATIENT SELECTION; PATIENT WITHDRAWAL; PERSONALIZED MEDICINE; PHENOTYPE; RESPONDER ANALYSIS; REVIEW; ST. GEORGE RESPIRATORY QUESTIONNAIRE; STUDY DESIGN; TREATMENT OUTCOME; CONVALESCENCE; DISEASE COURSE; EVIDENCE BASED MEDICINE; LUNG; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PATHOPHYSIOLOGY; PATIENT-REPORTED OUTCOME; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; LUNG; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; MODELS, STATISTICAL; PATIENT REPORTED OUTCOME MEASURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85007463581     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S117378     Document Type: Review

References (36)

1. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; 2016. www.goldcopd.org. Accessed July 16, 2016.
2. National Institute for Health and Care Excellence [webpage on the Internet]. Chronic Obstructive Pulmonary Disease Pathway; 2015. http://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-disease. Accessed August 24, 2015.
3. Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundation. COPD J Chronic Obstr Pulm Dis. 2013; 10(3):378–389.
4. European Medicines Agency. Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. London: European Medicines Agency; 2005.
5. US Department of Health and Human Services. Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment – Guidance for Industry. Silver Spring, MD; 2016. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071575.pdf. Accessed July 16, 2016.
6. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
7. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255.
8. Rennard SI. Minimal clinically important difference, clinical perspective: an opinion. COPD. 2005;2(1):51–55.
9. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–592.
10. Jones PW. St George’s Respiratory Questionnaire: MCID. COPD. 2005; 2(1):75–79.
11. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;7: CD009285.
12. Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013;14:100.
13. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546.
14. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6): 1321–1327.
15. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155(4): 1283–1289.
16. Welling JB, Hartman JE, Ten Hacken NH, Klooster K, Slebos D-J. The minimal important difference for the St George’s Respiratory Questionnaire in patients with severe COPD. Eur Respir J. 2015; 46(6):1598–1604.
17. Agusti A, Calverley PM, Celli B, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
18. Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care. 2001;39(10):1039–1047.
19. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19(3): 398–404.
20. Jones PW, Gelhorn H, Wilson H, et al. Responder analyses for treatment effects in COPD using the SGRQ appear to be largely independent of the value used to determine a clinically significant response. Am J Respir Crit Care Med. 2015;191:A4454.
21. Jones PW, Leidy NK, Hareendran A, Lamarca R, Chuecos F, Garcia Gil E. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the evaluating respiratory symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res. 2016;17:61.
22. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494.
23. Beeh K-M, Beier J, Donohue JF. Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res. 2012;13:52.
24. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
25. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15): 1543–1554.
26. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364(12):1093–1103.
27. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127(3):809–817.
28. Laviolette L, Bourbeau J, Bernard S, et al. Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax. 2008; 63(2):115–121.
29. Landsberger HA. Hawthorne Revisited. Ithaca, NY: The New York State School of Industrial and Labor Relations; 1958.
30. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7(1):30.
31. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34(1):215–220.
32. Jones PW, Gelhorn H, Wilson H, et al. Effect of bronchodilator and placebo therapy on SGRQ score in patients over 3 years: difference between low/medium and high socio-economic countries. Am J Respir Crit Care Med. 2014;189(Meeting Abstracts):A5962.
33. Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654.
34. Singh D, Worsley S, Zhu C-Q, Hardaker L, Church A. Umeclidinium/ vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15:91.
35. Jones PW. Responsiveness of the COPD Assessment Test: the minimal clinically important difference does matter (response). Chest. 2012;142(1):267–268.
36. Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203.